Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

OBJECTIVE: Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene‐related peptide (CGRP) ligand or receptor (CGRP mAb) for the preventive treatment of migraine. BACKGROUND: The efficacy of CGR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Headache
Autors principals: Berman, Gary, Croop, Robert, Kudrow, David, Halverson, Philip, Lovegren, Meghan, Thiry, Alexandra C., Conway, Charles M., Coric, Vladimir, Lipton, Richard B.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Research Submissions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496574/
https://ncbi.nlm.nih.gov/pubmed/32799325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13930
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars